VBL THERAPEUTICS

company

About

VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
€2.50M
Industries
Biotechnology,Genetics,Health Care,Medical
Founded date
Jan 1, 2000
Number Of Employee
1 - 10
Operating Status
Active

VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs.

VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€17.50M
VBL THERAPEUTICS has raised a total of €17.50M in funding over 2 rounds. Their latest funding was raised on Dec 20, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 20, 2021 Grant €2.50M 1 European Innovation Council Detail
Dec 20, 2021 Post-IPO Equity €15M 1 European Innovation Council Detail

Investors

Number of Lead Investors
Number of Investors
2
1
VBL THERAPEUTICS is funded by 1 investors. European Innovation Council are the most recent investors.
Investor Name Lead Investor Funding Round
European Innovation Council Yes Grant